Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Melodiol Global Health Ltd.

Healthcare AU ME1

NoneAUD
-(-%)

Last update at 2024-12-10T00:00:14.191264Z

Day Range

--
LowHigh

52 Week Range

0.0011.20
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap1.13M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.17100M
  • Revenue TTM18.92M
  • Revenue Per Share TTM4.07
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-7.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -32.78000M -30.03097M -30.77958M
Minority interest - - -
Net income -32.78200M -30.03097M -30.77958M
Selling general administrative 16.67M 26.98M 9.71M
Selling and marketing expenses - - -
Gross profit 0.37M - 0.14M
Reconciled depreciation - - -
Ebit - - -
Ebitda - - -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -32.24500M -30.03097M -30.77958M
Other operating expenses - - -
Interest expense - 0.52M 4.93M
Tax provision 0.00200M 0.00000M 0.00000M
Interest income 0.38M - -
Net interest income - - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 8.77M 6.22M 2.45M
Total operating expenses - - -
Cost of revenue 8.40M - 2.30M
Total other income expense net - - -
Discontinued operations - - -
Net income from continuing ops - - -
Net income applicable to common shares -32.78200M -30.03097M -30.77958M
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 37.98M 29.31M 19.12M
Intangible assets 15.85M 8.31M 1.28M
Earning assets - - -
Other current assets - 0.46M 0.14M
Total liab 15.69M 1.56M 5.47M
Total stockholder equity 22.29M 27.76M 13.65M
Deferred long term liab - - -
Other current liab - - -
Common stock 128.38M 109.95M 71.79M
Capital stock - - -
Retained earnings -108.99600M -83.57492M -58.44313M
Other liab - - -
Good will - - -
Other assets 0.29M 0.42M -
Cash - - -
Cash and equivalents 1.39M 7.18M 6.05M
Total current liabilities 15.69M 1.56M 5.47M
Current deferred revenue - - -
Net debt - - -
Short term debt 0.00000M 0.00000M 3.26M
Short long term debt - - -
Short long term debt total - - -
Other stockholder equity 2.91M 1.38M 0.30M
Property plant equipment 9.98M 10.44M 9.91M
Total current assets 11.87M 10.14M 7.94M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables 1.89M 1.10M 0.64M
Long term debt - - -
Inventory 5.77M 1.40M 1.11M
Accounts payable - - -
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total - - -
Capital lease obligations - - -
Long term debt total 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments - - -
Change to liabilities - - -
Total cashflows from investing activities -2.28400M -1.37146M -0.83169M
Net borrowings - - -
Total cash from financing activities 13.81M 24.89M 13.65M
Change to operating activities - - -
Net income - - -
Change in cash -5.79600M 1.14M 3.25M
Begin period cash flow - - -
End period cash flow - - -
Total cash from operating activities -17.30600M -22.37792M -9.62158M
Issuance of capital stock - - -
Depreciation - - -
Other cashflows from investing activities -1.93600M -0.91715M -0.40254M
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock 9.34M 25.09M 10.75M
Other cashflows from financing activities -0.11700M 0.00000M -2.19203M
Change to netincome - - -
Capital expenditures 0.35M 0.45M 0.43M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -0.42400M 0.00000M 0.00032M
Stock based compensation - - -
Other non cash items - - -
Free cash flow - - -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ME1
Melodiol Global Health Ltd.		 - -% - - - 0.06 0.41 0.53 -1.7112
AFP
AFT Pharmaceuticals Ltd		 0.17 7.00% 2.60 22.70 19.61 1.19 2.63 1.40 13.35
VLS
Vita Life Sciences Ltd		 -0.14 5.88% 2.24 14.88 - 1.65 2.51 1.30 7.67
SNT
Syntara Limited		 0.001 1.96% 0.05 - 20.45 10.56 4.66 6.32 -2.1607
MVP
Medical Developments International		 0.005 0.92% 0.55 - 166.67 1.60 1.10 1.19 278.77

Reports Covered

Stock Research & News

View All

Profile

Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Melodiol Global Health Ltd.

145 Stirling Highway, Nedlands, WA, Australia, 6009

Key Executives

Name Title Year Born
Mr. Boaz Wachtel M.A., M.D., MBA Co-Founder & Non-Executive Chairman 1960
Mr. William Lay B.Com. Group CEO, MD & Director NA
Mr. Christopher Grundy BCom, FCA, FCIS, GAICD Chief Financial Officer NA
Ms. Micheline MacKay B.Sc., M.Sc., P.M.P. Executive Director NA
Ms. Jodi Scott M.Sc. Executive Director NA
Dr. Gian Trepp Commercial & Marketing Director NA
Mr. Mitchel Fleming Managing Director of Halucenex NA
Brett Ayers Managing Director of Impactive NA
Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom Joint Company Secretary 1970
Hon. Brian Walker Strategic Consultant & Chair of Scientific Advisory Committee NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.